Zynerba Pharmaceuticals, Inc.
ZYNE · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $22,611 | $113,067 | $89,176 | $132,881 |
| - Cash | $50,641 | $67,808 | $59,157 | $70,063 |
| + Debt | $334 | $563 | $110 | $353 |
| Enterprise Value | -$27,695 | $45,822 | $30,128 | $63,171 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$34,620 | -$36,211 | -$52,063 | -$34,174 |
| % Margin | – | – | – | – |
| Net Income | -$34,820 | -$37,601 | -$50,404 | -$31,433 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.82 | -0.96 | -1.87 | -1.43 |
| % Growth | 14.6% | 48.7% | -30.8% | – |
| Operating Cash Flow | -$23,027 | -$33,457 | -$41,314 | -$34,818 |
| Capital Expenditures | -$154 | -$48 | -$445 | -$129 |
| Free Cash Flow | -$23,181 | -$33,505 | -$41,759 | -$34,947 |